|Bid||102.50 x 1000|
|Ask||125.20 x 800|
|Day's Range||120.62 - 124.96|
|52 Week Range||57.24 - 124.97|
|Beta (5Y Monthly)||1.39|
|PE Ratio (TTM)||4.31|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Jul 02, 2010|
|1y Target Est||N/A|
Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ligand Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating
LGND vs. TECH: Which Stock Is the Better Value Option?
The main point of investing for the long term is to make money. Furthermore, you'd generally like to see the share...
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
It is now my pleasure to turn today's program over to Patrick O'Brien, SVP, Investor Relations at Ligand's Pharmaceuticals. Speaking for Ligand today will be John Higgins, CEO; Matt Foehr, COO; and Matt Korenberg, CFO.
Ligand (LGND) delivered earnings and revenue surprises of 45.90% and 27.30%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
Ligand (LGND) delivered earnings and revenue surprises of 4.41% and 8.27%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Anyone researching Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) might want to consider the historical volatility...
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]
Ligand (LGND) reports lower-than-expected third-quarter 2019 earnings. It also lowers outlook for 2019 earnings. However, revenues were better than expected.
Ligand (LGND) delivered earnings and revenue surprises of -24.62% and 7.12%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?